Drug Profile
ATL 1101
Alternative Names: ATL1101Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Murdoch Childrens Research Institute
- Developer Antisense Therapeutics; University of British Columbia; Vancouver General Hospital
- Class Antineoplastics; Antipsoriatics; Antisense oligonucleotides
- Mechanism of Action Insulin-like growth factor I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Prostate cancer
- Discontinued Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in Canada (SC, Injection)
- 02 Jun 2014 Preclinical development is ongoing for Prostate cancer
- 20 Jul 2012 The option period has expired for Afandin's option to license agreement with Antisense Therapeutics for ATL 1101, with no extension of the agreement available